Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Validation of Lung EpiCheck®, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals

Mina Gaga, Joanna Chorostowska-Wynimko, Ildikó Horváth, Martin C Tammemagi, David Shitrit, Vered H Eisenberg, Hao Liang, David Stav, Dan Levy Faber, Maarten Jansen, Yael Raviv, Vasileios Panagoulias, Piotr Rudzinski, Gabriel Izbicki, Ohad Ronen, Adiv Goldhaber, Rawia Moalem, Nadir Arber, Ilana Haas, Qinghau Zhou
European Respiratory Journal 2020; DOI: 10.1183/13993003.02682-2020
Mina Gaga
17th Respiratory Medicine Department, Athens Chest Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mina Gaga
Joanna Chorostowska-Wynimko
2National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joanna Chorostowska-Wynimko
Ildikó Horváth
3National Korányi Institute of Pulmonology, Budapest, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin C Tammemagi
4Brock University, St. Catharines, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Shitrit
5Pulmonary Department, Meir Medical Center, Kfar Saba, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vered H Eisenberg
6Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hao Liang
7Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Stav
8Lung Institute, Maccabi Health Services Hashalom, Tel-Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Levy Faber
9Department of Cardiothoracic surgery, Lady Davis Carmel Medical Center, Haifa, Israel; Ruth and Bruch Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maarten Jansen
10Pulmonary Department, Ziekenhuisgroep Twente, Hengelo, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yael Raviv
11Department of Medicine, Pulmonology Institute, Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vasileios Panagoulias
12Respiratory Medicine Department, Athens Chest Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piotr Rudzinski
2National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriel Izbicki
13Pulmonary Institute, Shaare Zedek Medical Center, Jerusalem, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ohad Ronen
14Department of Otolaryngology - Head and Neck Surgery, Galilee Medical Center affiliated with Azrieli Faculty of Medicine, Safed, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adiv Goldhaber
15Family Physician, Clalit Health Services, Raanana, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rawia Moalem
16Gastroenterology Institute, The Holy Family Hospital, Nazareth, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadir Arber
17Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Centre, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilana Haas
18Breast unit, Meir Medical Center, Kfar Saba, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qinghau Zhou
7Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Qinghau Zhou
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Aim Lung cancer screening reduces mortality. We aim to validate the performance of Lung EpiCheck®, a 6-marker panel methylation-based plasma test, in the detection of lung cancer in European and Chinese samples.

Methods A case-control European training set (102 lung cancer cases/265 controls) was used to define the panel and algorithm. Two cut-offs were selected, low cut-off (LCO) for high sensitivity and high cut-off (HCO) for high specificity. The performance was validated in case-control European and Chinese validation sets (cases/controls: 179/137 and 30/15).

Results The European and Chinese validation sets achieved AUCs of 0.882 and 0.899, respectively. The respective sensitivity/specificity with LCO were 87.2%/64.2% and 76.7%/93.3% and with HCO were 74.3%/90.5% and 56.7%/100.0%, respectively. Stage I NSCLC sensitivity in European and Chinese samples with LCO was 78.4% and 70.0% and with HCO was 62.2% and 30.0%, respectively. SCLC was represented only in the European set and sensitivities with LCO and HCO were 100.0% and 93.3%. In multivariable analyses of the European validation set, the assay's ability to predict lung cancer was independent of established risk factors (age, smoking, COPD), and overall AUC was 0.942.

Conclusions Lung EpiCheck demonstrated strong performance in lung cancer prediction in case-control European and Chinese samples, detecting high proportions of early stage NSCLC and SCLC and significantly improving predictive accuracy when added to established risk factors. Prospective studies are required to confirm these findings. Utilising such a simple and inexpensive blood test has the potential to improve compliance and broaden access to screening for at-risk populations.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Yan reports grants from National Institutes of Health, during the conduct of the study;.

Conflict of interest: Dr. Gaga has nothing to disclose.

Conflict of interest: Dr. Chorostowska-Wynimko reports grants, personal fees and non-financial support from Grifols, grants, personal fees and non-financial support from AstraZeneca, grants, personal fees and non-financial support from Pfizer, personal fees and non-financial support from MSD, personal fees and non-financial support from BMS, personal fees from GSK, personal fees from Novartis, personal fees from Chiesi, personal fees from Roche, grants and personal fees from Boehringer-Ingelheim, grants, personal fees and non-financial support from CSL Behring, grants, personal fees and non-financial support from CelonPharma, personal fees from Amgen, personal fees from Lekam, outside the submitted work;.

Conflict of interest: Dr. Horvath reports personal fees from AstraZeneca, personal fees from Novartis, personal fees from CSL Behring, personal fees from Boeringer-Ingelheim, personal fees from GSK, personal fees from Berlin-Chemie, from null, outside the submitted work;.

Conflict of interest: As of January 2019, Tammemagi has served as consultant to Johnson & Johnson/Janssen, Medial EarlySign, Nucleix, bioAffinity Technologies, AstraZeneca. Dr Tammemagi has serve as consultant for these companies providing advice on the design and analysis of biomarker or lung cancer screening studies or on cancer risk prediction modelling.

Conflict of interest: Dr. shitrit has nothing to disclose.

Conflict of interest: Dr. Eisenberg has nothing to disclose.

Conflict of interest: Dr. liang has nothing to disclose.

Conflict of interest: Dr. Levy Faber has nothing to disclose.

Conflict of interest: Dr. Jansen has nothing to disclose.

Conflict of interest: Dr. Raviv has nothing to disclose.

Conflict of interest: Dr. Panagoulias has nothing to disclose.

Conflict of interest: Dr. Rudzinski has nothing to disclose.

Conflict of interest: Dr. Izbicki has nothing to disclose.

Conflict of interest: Dr. Ronen has nothing to disclose.

Conflict of interest: Dr. Goldhaber has nothing to disclose.

Conflict of interest: Dr. Arber has nothing to disclose.

Conflict of interest: Dr. Haas Hamish has nothing to disclose.

Conflict of interest: Dr. Zhou has nothing to disclose.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received July 9, 2020.
  • Accepted October 7, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

PreviousNext
Back to top
View this article with LENS
Vol 59 Issue 6 Table of Contents
European Respiratory Journal: 59 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Validation of Lung EpiCheck®, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Validation of Lung EpiCheck®, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals
Mina Gaga, Joanna Chorostowska-Wynimko, Ildikó Horváth, Martin C Tammemagi, David Shitrit, Vered H Eisenberg, Hao Liang, David Stav, Dan Levy Faber, Maarten Jansen, Yael Raviv, Vasileios Panagoulias, Piotr Rudzinski, Gabriel Izbicki, Ohad Ronen, Adiv Goldhaber, Rawia Moalem, Nadir Arber, Ilana Haas, Qinghau Zhou
European Respiratory Journal Jan 2020, 2002682; DOI: 10.1183/13993003.02682-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Validation of Lung EpiCheck®, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals
Mina Gaga, Joanna Chorostowska-Wynimko, Ildikó Horváth, Martin C Tammemagi, David Shitrit, Vered H Eisenberg, Hao Liang, David Stav, Dan Levy Faber, Maarten Jansen, Yael Raviv, Vasileios Panagoulias, Piotr Rudzinski, Gabriel Izbicki, Ohad Ronen, Adiv Goldhaber, Rawia Moalem, Nadir Arber, Ilana Haas, Qinghau Zhou
European Respiratory Journal Jan 2020, 2002682; DOI: 10.1183/13993003.02682-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF

Subjects

  • Lung cancer
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volumes and survival in chronic lung allograft dysfunction
  • Social consequences of sleep disordered breathing
  • Diagnosing airflow obstruction in COPD
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society